Literature DB >> 22767444

Bridging the gap: advances in artificial liver support.

Scott L Nyberg1.   

Abstract

KEY POINTS: 1. The goals of liver support therapy include the following: To provide detoxification and synthetic function during liver failure. To remove or reduce the production of proinflammatory cytokines to correct the systemic inflammatory response of liver failure. To stimulate the regeneration of the injured liver and increase the likelihood of spontaneous recovery. 2. There is a large unmet need for a liver support device because of the shortage of organs for liver transplantation and the risks of major surgery. 3. Liver support devices can be divided into 2 groups: purely mechanical artificial devices and cell-based bioartificial devices. Both provide detoxification, but bioartificial liver devices provide the option of synthetic function and biotransformation activities that are not possible with a purely mechanical device. 4. An abundant high-quality supply of human hepatocytes is not currently available for liver cell therapy. However, such a supply is essential for successful bioartificial liver therapy. Novel options are under development for the unlimited production of high-quality human hepatocytes.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22767444     DOI: 10.1002/lt.23506

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  16 in total

1.  Spheroid culture for enhanced differentiation of human embryonic stem cells to hepatocyte-like cells.

Authors:  Kartik Subramanian; Derek Jason Owens; Ravali Raju; Meri Firpo; Timothy D O'Brien; Catherine M Verfaillie; Wei-Shou Hu
Journal:  Stem Cells Dev       Date:  2013-10-22       Impact factor: 3.272

Review 2.  Extracorporeal Liver Support in Patients with Acute Liver Failure.

Authors:  Joshua A Villarreal; Norman L Sussman
Journal:  Tex Heart Inst J       Date:  2019-02-01

Review 3.  The road to regenerative liver therapies: the triumphs, trials and tribulations.

Authors:  Ravali Raju; David Chau; Catherine M Verfaillie; Wei-Shou Hu
Journal:  Biotechnol Adv       Date:  2013-09-19       Impact factor: 14.227

4.  Machine perfusion enhances hepatocyte isolation yields from ischemic livers.

Authors:  Maria-Louisa Izamis; Sinem Perk; Candice Calhoun; Korkut Uygun; Martin L Yarmush; François Berthiaume
Journal:  Cryobiology       Date:  2015-07-16       Impact factor: 2.487

Review 5.  Cell therapy in chronic liver disease.

Authors:  Clara T Nicolas; Yujia Wang; Scott L Nyberg
Journal:  Curr Opin Gastroenterol       Date:  2016-05       Impact factor: 3.287

6.  Therapeutic targets for liver regeneration after acute severe injury: a preclinical overview.

Authors:  Hidenobu Kojima; Kojiro Nakamura; Jerzy W Kupiec-Weglinski
Journal:  Expert Opin Ther Targets       Date:  2020-01-10       Impact factor: 6.902

Review 7.  Acute-on-chronic liver failure: terminology, mechanisms and management.

Authors:  Shiv K Sarin; Ashok Choudhury
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-03       Impact factor: 46.802

8.  Continuous molecular adsorbent recirculating system treatment in 69 patients listed for liver transplantation.

Authors:  Per Olin; John Hausken; Aksel Foss; Tom Hemming Karlsen; Espen Melum; Håkon Haugaa
Journal:  Scand J Gastroenterol       Date:  2015-04-11       Impact factor: 2.423

9.  A preliminary study for constructing a bioartificial liver device with induced pluripotent stem cell-derived hepatocytes.

Authors:  Masaya Iwamuro; Hidenori Shiraha; Shuhei Nakaji; Masumi Furutani; Naoya Kobayashi; Akinobu Takaki; Kazuhide Yamamoto
Journal:  Biomed Eng Online       Date:  2012-12-07       Impact factor: 2.819

Review 10.  Potential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases Treatment.

Authors:  Yue Yu; Xuehao Wang; Scott L Nyberg
Journal:  J Clin Med       Date:  2014-09-05       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.